Superbugs, Magnets & More: Medicine’s Comeback Kids
Monday, March 16
9:30AM - 10:30AM
110 E 2nd St
We think of medicine and technology ever moving forward in a march of progress, moving from one success to the next. But the history of science is far from simple, and it often repeats itself. Infectious diseases were declared a thing of the past in the 1960s, but now they’ve returned with a vengeance and threaten to overwhelm our more sophisticated medicines. Medical treatments once dismissed as backward—such as applying magnets to the brain or unleashing viruses on pathogenic bacteria--have gained new luster and are being taken up by major research organizations and pharmaceutical companies. In this session, join us to explore the forces that are making what was old new again—from the shortcomings of modern healthcare to the incentives for resurrecting lost ideas.
Chairman & Sr Partner
Bennett Shapiro MD is senior partner and chair of PureTech, a science & technology R & D company. Prior to joining PureTech, Dr. Shapiro was executive vice president of Merck Research Laboratories ...Show the rest
Bennett Shapiro MD is senior partner and chair of PureTech, a science & technology R & D company. Prior to joining PureTech, Dr. Shapiro was executive vice president of Merck Research Laboratories where he initially led all basic and preclinical research activities worldwide and then all of Merck's external research. Dr. Shapiro led the research program that resulted in FDA registration of approximately 25 drugs and vaccines. Prior to Merck, Shapiro was a professor and chairman of the Department of Biochemistry at the University of Washington. He is the author of over 120 papers on the molecular regulation of cellular behavior and the biochemical events that integrate the cascade of cellular activations at fertilization. He has served on many institutional advisory boards and scientific review panels, and is currently a member of the board of the Drugs for Neglected Disease Initiative (Doctors Without Borders), and a co-founder and board member of Tal Medical (clinical stage medical device company developing a novel neurostimulation based treatment for psychiatric disorders), Vedanta Biosciences (a company developing a new class of drugs to modulate the human microbiome), and Akili (developing clinically-validated cognitive therapeutics, assessments and diagnostics that look and feel like high-quality video games).Hide the rest
The New York Times
Carl Zimmer is a columnist at the New York Times, where his column “Matter” appears each Thursday. In his books, essays & articles, Zimmer reports from the frontiers of biology, where scientists ar...Show the rest
Carl Zimmer is a columnist at the New York Times, where his column “Matter” appears each Thursday. In his books, essays & articles, Zimmer reports from the frontiers of biology, where scientists are expanding our understanding of life. He is a popular speaker at universities, medical schools, and museums and a guest on the radio programs Radiolab and This American Life.
Zimmer is a lecturer at Yale University, where he teaches writing about science and the environment. He was the first Visiting Scholar at the Science, Health, and Environment Reporting Program at NYU’s Arthur L. Carter Journalism Institute. He has won fellowships from the Guggenheim Memorial Foundation and the Alfred P. Sloan Foundation, and the AAAS's Journalism Award three times. His other honors include the Pan-American Health Organization Award for Excellence in International Health Reporting, the American Institute Biological Sciences Media Award, & the National Academies Science Communication Award among others.Hide the rest